{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-045035","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2023-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.343700+00:00","generated_at":"2026-06-07T11:51:23.204918+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Propanc Biopharma issues $150K convertible note to One44 Capital at 10% interest, 60% conversion discount","bullets":["Principal $150K; purchase price $135K (15% OID); 10% interest; maturity Dec 8, 2024.","Convertible at 60% of lowest trading price over prior 15 days; subject to 4.99% beneficial ownership cap.","Issued under Regulation D private placement; net proceeds for working capital.","Prepayment option: 115% within 60 days, 130% 61-120 days, 140% 121-180 days; none after 180 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-045035","json":"https://secwatch.observer/filing/0001493152-23-045035.json","markdown":"https://secwatch.observer/filing/0001493152-23-045035.md","text":"https://secwatch.observer/filing/0001493152-23-045035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223045035/0001493152-23-045035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223045035/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:51:23.204918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f859efd36c9c721ee6217cb25bff2e257fa5727","claim":"Propanc Biopharma, Inc. incurred convertible notes of $150,000 with Investor at ten percent (10%) per annum maturing December 8, 2024.","evidence_excerpt":"entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $150,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223045035/0001493152-23-045035-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$150,000"},{"label":"Counterparty","value":"Investor"},{"label":"Rate","value":"ten percent (10%) per annum"},{"label":"Maturity","value":"December 8, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"710d8647af9e7cba1cf00a3b1fd61164a5889a00","claim":"Propanc Biopharma, Inc. entered into Purchase Agreement with an investor valued at principal amount of $150,000 (effective 2023-12-11).","evidence_excerpt":"Effective December 11, 2023, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $150,000 (the “Note”), for a purchase price of $135,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223045035/0001493152-23-045035-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an investor"},{"label":"Value","value":"principal amount of $150,000"},{"label":"Effective","value":"2023-12-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}